You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
The company will compete by continuing product improvements, ramping up marketing presence, and launching an app to improve doctor and consumer engagement.
The firm reported total revenu 16.8 million, up from $187.9 million in Q2 2018 and just above analysts' average estimate.
The company said it expects revenues from its ePlex analyzers to go up approximately 110 percent year over year for Q4.
The company's CEO noted softness in both its diagnostics and life science segment. The projected revenues would fall short of the consensus Wall Street estimate.
The firm expects Q4 revenues to be in the $132 million to $133 million range, up 15 to 16 percent from a year ago and consistent with the consensus Wall Street estimate.
The company expects to miss the consensus Wall Street revenue estimates for Q4 and full-year 2018.
In a preliminary financial report, the company said it is expecting revenues of more than $144 million and to have tested more than 300,000 samples.
The firm reported that it expects product and service revenue of approximately $23.5 million for the fourth quarter of last year and $83.5 million for full-year 2018.
The company said 100 US transplant centers provided its AlloSure kidney transplant test to almost 3,400 patients in Q4.
The company said it completed approximately 292,000 Cologuard tests during the fourth quarter.